Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Paul Richardson on the 17th IMW meeting

Paul Richardson • 13 Sep 2019
IMW 2019
Multiple Myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the 17th International Myeloma Workshop (IMW) meeting, specifically emphasizing the whopping 4000 attendees, 600 abstracts and the high representation of female faculty. This interview was recorded at the IMW 2019, held in Boston, MA.

More from Paul Richardson

Belantamab mafodotin combined with pomalidomide and dexamethasone in RRMM: HRQoL in DREAMM-8 4:20
Belantamab mafodotin combined with pomalidomide and dexamethasone in RRMM: HRQoL in DREAMM-8
Paul Richardson • 7 Dec 2025
STOMP: selinexor, mezigdomide, & dexamethasone in patients with RRMM 3:33
STOMP: selinexor, mezigdomide, & dexamethasone in patients with RRMM
Paul Richardson • 7 Dec 2025
The treatment landscape for patients with multiple myeloma at first relapse 3:32
The treatment landscape for patients with multiple myeloma at first relapse
Paul Richardson • 19 Sep 2025
Advances in the research of mezigdomide for multiple myeloma: the SUCCESSOR-1 and SUCCESSOR-2 trials 3:16
Advances in the research of mezigdomide for multiple myeloma: the SUCCESSOR-1 and SUCCESSOR-2 trials
Paul Richardson • 19 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals